AstraZeneca’s Fasenra Receives the US FDA Approval for Hypereosinophilic Syndrome

Why It Matters

The approval gives clinicians a targeted, antibody‑based option for a disease with limited therapies, potentially reducing hospitalizations and improving quality of life, while bolstering AstraZeneca’s revenue stream in the growing biologics market.

Key Takeaways

• FDA approves Fasenra for hypereosinophilic syndrome in patients 12+
• Phase III NATRON trial showed 65% risk reduction in HES flares
• 30 mg subcutaneous injection every 4 weeks added to standard HES therapy
• PROMIS fatigue scores improved, indicating better patient quality of life

Pulse Analysis

Hypereosinophilic syndrome (HES) is a rare, chronic disorder characterized by persistent eosinophil overproduction that can damage heart, lung, and nervous tissue. Incidence estimates range from 0.5 to 1 case per 100,000 people, and patients often endure recurrent flares despite corticosteroids or cytotoxic agents, which carry substantial toxicity. AstraZeneca’s Fasenra, a monoclonal antibody that depletes eosinophils by binding the IL‑5 receptor α chain, has been approved for severe eosinophilic asthma since 2017. Extending its label to HES reflects a broader therapeutic strategy of repurposing established biologics for orphan indications.

The pivotal NATRON Phase III trial enrolled 133 adolescents and adults with HES and randomized them to receive 30 mg of Fasenra subcutaneously every four weeks or placebo, both alongside standard background therapy. Over 24 weeks, the primary endpoint—time to first HES worsening or flare—was delayed, translating to a 65% relative risk reduction versus placebo. Secondary analyses revealed fewer total flares, a lower annualized flare rate, and sustained improvements in PROMIS fatigue scores, indicating not only clinical control but also measurable quality‑of‑life gains for patients.

From a commercial perspective, the new indication adds a high‑margin biologic to AstraZeneca’s oncology‑adjacent portfolio, positioning the company against niche players such as mepolizumab and reslizumab, which are also eosinophil‑targeting agents. The approval is likely to generate several hundred million dollars in U.S. sales over the next five years, given the orphan‑drug premium and limited competition. Moreover, the success may spur further investigations of benralizumab in other eosinophil‑driven diseases, reinforcing the trend of leveraging existing antibody platforms to address unmet medical needs.